My logic vis-à-vis ribavirin use for cirrhotic patients is that cirrhotic patients may not be in good enough health to get multiple chances at a cure, so one should give them the “full regimen” in the first-line setting. I’d rather start a cirrhotic patient on ribavirin and have to reduce (or eliminate) it in midstream than to omit ribavirin from the outset and thereby cause a treatment failure.
I’m not dogmatic about this, however. For any given patient, there are several variables to consider in making a treatment decision.
Market Data 
Markets 
AI
